Drug Utilization Review Board (DURB) Agenda

July 23, 2021 - 9:00 am

United States

Meeting Location: 
Microsoft Office Teams Live Event

Due to the COVID-19 pandemic, this meeting will be conducted virtually using Microsoft Teams only.  Join the meeting here.

There is not a physical location for this meeting.

Closed captioning for this meeting is available.  Viewers are asked to highlight the closed captioning symbol "cc" on the bottom of their viewing screen to enable this function. 

Attendees who would like to provide public comment should see the Public Comment section below.

  1. Call to order
  2. Consideration of minutes from April 23, 2021, meeting (vote required)
  3. Amendments proposed to Texas Administrative Code concerning the Drug Utilization Review Board and conflict of interest policy 
  4. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
    1. Alzheimers agents
    2. Antihistamines, minimally sedating
    3. Antihypertensives, sympatholytic
    4. Calcium channel blockers
    5. Cephalosporins and related antibiotics
    6. Cytokine and cell adhesion module antagonists and related agents
    7. Fluoroquinolones, oral
    8. Glucocorticoids, oral
    9. Immunosuppressives, oral
    10. Iron, oral
    11. Leukotriene modifiers
    12. Nonsteroidal anti-inflammatory drugs (NSAIDs)
    13. Ophthalmic antibiotics
    14. Ophthalmic antibiotic-steroid combinations
    15. Ophthalmics for allergic conjunctivitis
    16. Ophthalmics, anti-inflammatories
    17. Ophthalmic, anti-inflammatories/immunomodulators
    18. Ophthalmics, glaucoma agents
    19. Otic antibiotics
    20. Otic anti-infectives and anesthetics
    21. Penicillins
    22. Platelet aggregation inhibitors
    23. Progestational agents
    24. Rosacea agents, topical
    25. Skeletal muscle relaxants
    26. Steroids, topical
    27. aa. Ulcerative colitis agents
  5. Public comment on single new drugs to be reviewed for the Medicaid PDL:
    1. Hetlioz liquid (oral) / Sedative-hypnotics
    2. Ponvory starter pack (oral) / Multiple sclerosis agents
    3. Ponvory tablet (oral) /  Multiple sclerosis agents
    4. Qelbree (oral) / Stimulants and related agents
    5. Tepmetko tablet (oral) / Oncology, oral - lung
    6. Trilociclo kit (topical) / Antifungals, topical
    7. Ukoniq (oral) / Oncology, oral - hematologic
    8. Vesicare LS (oral) / Bladder relaxant preparations
  6. Therapeutic and clinical drug reviews and updates:   Magellan Medicaid Administration
  7. Executive work session

Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

  1. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
  2. Retrospective drug utilization review (DUR):  Conduent, LLC
    1. Report on recent retrospective DUR interventions:
      1. Benzodiazepines anxiolytics and/or controlled sedative-hypnotics
      2. Major depressive disorder (MDD) management
    2. Report on recent retrospective DUR intervention outcomes:
      1. Asthma
      2. Pharmacotherapy of post-traumatic stress disorder
      3. Gabapentinoid drug use evaluation
      4. Overutilization of antibiotics
    3. Retrospective DUR proposals: (vote required)
      1. Bipolar disorder
      2. Hypertension
  3. Prospective prior authorization proposals (clinical edits):  KEPRO, LLC (vote required)
    1. Attention-Deficit / Attention Deficit Hyperactivity Disorder
      1. Add Qelbree  
    2. Multiple sclerosis agents
      1. New criteria for Ponvory (safety checks)
    3. Phosphate Binders
      1. Criteria revisions
    4. Sedative/Hypnotics
      1. Criteria revision for Hetlioz
  4. Retrospective drug use criteria for outpatient use in Vendor Drug Program:
    The University of Texas at Austin College of Pharmacy (vote required)
    1. Acetylcholinesterase inhibitors
    2. Cyclooxygenase-2 inhibitors
    3. Histamine H2-receptor antagonists
    4. Ketorolac (oral)
    5. Leukotriene receptor antagonists
    6. Mecasermin
    7. Memantine
  5. Next meeting date:  October 22, 2021
  6. Adjourn

Public Comment: The Texas Health and Human Services Commission (HHSC) welcomes public comments pertaining to topics related to DURB and Medicaid PDL. Members of the public who would like to pre-register to provide oral comments at the meeting or to provide written comments are asked to complete a Public Comment form here.

To register to provide oral comments, please mark the correct box on the Public Comment form and submit a completed Public Comment Form, HHS Form 1320. Instructions for providing oral comments will be emailed to you. Registration for oral public comment is due no later than 5:00 p.m., Wednesday, July 21, 2021. Members of the public may also use the Microsoft Teams Live Event Q&A section during the meeting to submit a request to provide oral public comment. The request must contain your name and either the organization you are representing or that you are speaking as a private citizen and your direct phone number. Do not include confidential information or protected health information in comments.

Public comment is limited to three minutes. Each speaker must state their name and either the organization they are representing or that they are speaking as a private citizen. If you register to speak and wish to provide a handout before the meeting, please submit an electronic copy in accessible PDF format. Handouts are limited to two pages (paper size: 8.5” by 11”, one side only). Handouts must be emailed to HHSC immediately after registering and include the name of the person who will be commenting. Do not include confidential information or protected health information in handouts. Staff will not read handouts aloud during the meeting, but handouts will be provided to Board members and State staff. It is not permissible for public speakers to interject or ask questions to committee members during the rest of the meeting.

A member of the public may provide written public comment by submitting their written public comment with the completed Written Public Comment form, HHS Form 1334, emailed to VDP-Advisory@hhsc.state.tx.us no later than 5:00 p.m., July 12, 2021. Please include your name and either the organization you are representing or that you are speaking as a private citizen. Written comments are limited to ten pages and will be made available to DURB Board members for their consideration prior to the meeting. Staff will not read written comments aloud during the meeting. Comments should not include confidential information or protected health information.

Note: These procedures may be revised at the discretion of HHSC.

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services, 512-552-7672, and VDP-Advisory@hhsc.state.tx.us.

This meeting is open to the public.  No reservations are required, and there is no cost to attend this meeting.

Persons who want to attend the meeting and require assistive technology or services should contact Castoreno at 512-552-7672 or VDP-Advisory@hhsc.state.tx.us at least 72 hours before the meeting so appropriate arrangements can be made.